Approach to the patients with inadequate response to colchicine in familial Mediterranean fever

A Gül - Best Practice & Research Clinical Rheumatology, 2016 - Elsevier
Familial Mediterranean fever (FMF) is the most common form of monogenic
autoinflammatory conditions, and response to colchicine has been considered as one of its …

[HTML][HTML] Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments

S Ozen, I Kone-Paut, A Gül - Seminars in arthritis and rheumatism, 2017 - Elsevier
Abstract Background Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory
syndrome characterized by recurrent serositis or arthritis attacks and, in some patients …

Current therapeutic options for managing familial Mediterranean fever

ED Batu, ZS Arici, Y Bilginer, S Özen - Expert Opinion on Orphan …, 2015 - Taylor & Francis
Introduction: Familial Mediterranean fever (FMF) is a monogenic auto-inflammatory disease
characterized by recurrent attacks of fever and serositis. Although colchicine prevents the …

[HTML][HTML] The use of interleukine-1 inhibitors in familial Mediterranean fever patients: a narrative review

V Hentgen, C Vinit, A Fayand… - Frontiers in …, 2020 - frontiersin.org
Purpose: Familial Mediterranean fever (FMF) is the most common monogenic auto-
inflammatory disease characterized by recurrent attacks of fever and serositis. It is …

Anakinra for colchicine‐resistant familial Mediterranean fever: a randomized, double‐blind, placebo‐controlled trial

I Ben‐Zvi, O Kukuy, E Giat, E Pras, O Feld… - Arthritis & …, 2017 - Wiley Online Library
Objective Familial Mediterranean fever (FMF) is refractory to colchicine prophylaxis in 10–
20% of patients. In a number of patient series, treatment with anakinra, an interleukin‐1 …

[PDF][PDF] IL-1 inhibition in familial Mediterranean fever: clinical outcomes and expectations

F Kharouf, T Tsemach-Toren… - Clin Exp …, 2022 - clinexprheumatol.org
Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease, characterised
by recurrent episodes of fever and serositis. Since 1972, colchicine has been the drug of …

Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)

G El Hasbani, A Jawad, I Uthman - Orphanet journal of rare diseases, 2019 - Springer
Abstract Background Familial Mediterranean Fever (FMF), an autoinflammatory disease, is
characterized by self-limited inflammatory attacks of fever and polyserositis along with high …

Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial.

I Ben-Zvi, A Livneh - The Israel Medical Association journal: IMAJ, 2014 - europepmc.org
Familial Mediterranean fever (FMF) is a genetic auto-inflammatory disease characterized by
spontaneous short attacks of fever, elevated acute-phase reactants, and serositis …

Biologic therapy in familial Mediterranean fever

T Koga, K Migita, A Kawakami - Modern Rheumatology, 2016 - academic.oup.com
Familial Mediterranean fever (FMF) is the most common autoinflammatory hereditary
disease characterized by self-limited attacks of fever and serositis. Although colchicine is the …

Evidence-based recommendations for the practical management of Familial Mediterranean Fever

V Hentgen, G Grateau, I Kone-Paut, A Livneh… - Seminars in arthritis and …, 2013 - Elsevier
Abstract Aim Familial Mediterranean Fever (FMF) is the most common recurrent
autoinflammatory fever syndrome. Still, many issues—eg: colchicine dosage adjustment …